Digital transformation program stalled after missed go-lives — recovered before the third re-baseline

Two consecutive missed phased go-lives. A third re-baseline being drafted. A new CIO inheriting the trajectory. An independent recovery diagnostic produced a defensible recovery posture in 4 weeks — protecting an additional $18–22M in projected cost exposure and routing clinical-safety risk back to clinical governance.

Recovery Posture Signal delivered in 7 days

~$425K/week unproductive burn brought under explicit control

Engagement Snapshot

Client

Incoming CIO / CMIO / CFO (board pressure)

Engagement type

Project Recovery Diagnostic

Duration

4 weeks

Investment at risk

$68M program · $18–22M additional exposure if continued

Assurance depth

Integrated — Recovery Posture Signal + Stabilization Plan

Decision horizon

Immediate — third re-baseline pending

Scope

Multi-hospital regional EHR & clinical workflow modernization

Decision supported

Recover, restructure, or stop — defer the third re-baseline

Key Findings At A Glance

~70%

Gap perceived vs validated recoverability

12–15 mo

Additional delay surfaced

2,800+

Items reconciled against clinical readiness

$68M

Capital envelope protected

Context & Trigger

Assumed trajectory

The program team and the prior CIO believed a 9-month catch-up plan, supported by vendor escalation and additional capacity, would land the remaining go-live waves within the existing fiscal envelope. The third re-baseline was being prepared to formalize that catch-up.

Assumed trajectory

Validated delivery position

Independent validation identified 12–15 months of additional delivery time required under existing conditions, driven by decoupled clinical workflow validation, an unresolved integration backlog, and a vendor commercial structure that continued to reward activity over clinical readiness. Capital exposure under the existing trajectory: an additional $18–22M on top of the current envelope.

Delivery Position — Before Vs After Validation

Confidence gap — perceived vs validated recoverability

Perceived recoverability

85%

Validated recoverability

25%

Clinical readiness actually earned

30%

~70% confidence gap at Board level

Information Mix Shift

Before — decision basis

75% re-baseline narrative

25%

After — decision basis

15%

85% forensic clinical-readiness evidence

Recovery Posture Signal delivered in 7 days · ~$425K/week unproductive burn brought under explicit control

Context & Trigger

From diagnosis to recovery

1

Immediate mitigation

Deferred the third re-baseline pending validated recovery scope. Paused Wave 3 go-live planning until clinical workflow validation thresholds were defined. Reframed the program risk register to route clinical-safety items to dedicated clinical governance.

2

Waste containment

Excised non-essential workflow customization from near-term scope. Re-allocated capacity to clinical workflow validation, superuser readiness, and integrated testing on the critical path. Brought ~$425K/week of unproductive burn under explicit recovery-activity allocation.

3

Structural alignment

Re-coupled EHR configuration to clinical workflow validation milestones. Re-sequenced Wave 3 and Wave 4 go-lives behind validated clinical-readiness criteria. Re-negotiated commercial terms to shift vendor incentives from activity-based billing to outcome-based delivery.

4

Future assurance

Implemented integrated clinical-readiness telemetry tied to superuser sign-off and clinical workflow validation throughput. Embedded ongoing independent validation through network-wide go-live.

Assurance Verdict

Outcomes delivered

$68M

Capital secured

program envelope protected from a third re-baseline under unresolved clinical-readiness conditions

$18–22M

Exposure prevented

Additional capital exposure ruled out on evidence; recovery substituted for continuation

7 days

Recovery Posture Signal

Replaces typical multi-week re-baseline drafting cycle; recovery scope locked inside week one

12–15 mo

Schedule realism restored

Sponsor-perceived 9-month catch-up replaced with validated recovery posture and re-sequenced waves

Download

Full Case Study — Healthcare Digital Transformation: Recovery Diagnostic & Capital Protection

Complete forensic findings, root cause hierarchy, 90-day stabilization roadmap, and assurance operating model. Written for Board-level and executive review.

PDF · Full detail · No form required

Recognize a similar situation in your own program? We can help.

Get Started

Seeing similar signals in your own program?

Replan fatigue, clinical-readiness lagging activity, a new sponsor inheriting a trajectory, or clinical-safety risk quietly migrating onto the program risk register. We can validate the actual recoverability of the program — in 2 to 4 weeks, without disruption to clinical operations or execution cadence.

Looking for more detail? Download the Project Recovery Diagnostic brief.

Confidential

Findings shared only with the commissioning executive.

Independent

No vendor ties. Evidence-based, free from internal bias.

No obligation

Briefing is complimentary. Scope agreed before any commitment.

Explore More

More case studies

Competing Initiatives Creating Hidden Sequencing Risk Across The Portfolio

Public Sector · ERP Implementation

A Member-Owned Electric Cooperative Carrying $200M Of Active Capital Across Seven Concurrent Programs — Each Reporting Healthy At Program Level — With A General Rate Case Twelve Months Out And A Member-Board Capital Plan Review Behind It. An Independent Portfolio Review Surfaced Five Cross-Program Sequencing Dependencies And Produced A Defensible Re-Sequenced Capital Plan Ahead Of Regulatory Filing.

Strategic Vendor Missing Milestones Ahead Of A Multi-Year Renewal

Public Sector · ERP Implementation

A Mid-To-Large Omnichannel Retailer Six Months From Renewing A $45M Five-Year Strategic Tier-1 Vendor Contract — The Vendor Having Missed Three Of The Last Five Implementation Milestones, The CIO And CFO And CPO Not Yet Aligned On Whether To Renew, Renegotiate, Or Replace. An Independent Vendor Contract Review Reconstructed The Milestone-Miss Record, Quantified The Renegotiable Value, And Produced A Single Board-Defensible Renewal Posture Inside The Pre-Renewal Commercial Leverage Window.